30 km/h Direct Impact Against 242 mm-high Obstacle: TIGGO7 CSH Passes Mexico Battery Scrape Test Without Critical Damage
TIGGO7 CSH demonstrated outstanding battery protection capabilities following the severe impact, with only minor surface scratches visible on the battery casing and no signs of electrolyte leakage, fire, explosion, or smoke. The battery pack maintained excellent structural integrity, showing minimal bottom deformation while all high-voltage connectors remained fully operational.
The test conclusively validated the robust capabilities of Chery's "Guardian Battery" system. Its lithium iron phosphate blade battery provides an inherently stable chemical foundation, while the 780MPa high-strength steel underbody armor —combined with a chainmail-inspired structural design—effectively dissipates impact forces. The system's millisecond-response high-voltage cutoff technology (disconnecting circuits within 10ms) eliminates short-circuit risks, and its IP68-rated dustproof certification ensures reliable performance under the most challenging road conditions.
The Mexico battery scrape test marks the third stop of Chery Super Hybrid (CSH)'s global safety challenge tour, following rigorous evaluations in China including spiral rollover and dual-vehicle collision test, along with a grueling 53-hour saltwater immersion trial in Indonesia. Chery continues to validate its vehicles under six extreme global conditions—extreme cold, extreme heat, extreme dryness, extreme humidity, high-speed conditions, and rough terrain—positioning itself as the first Chinese automaker to conduct comprehensive extreme safety validation overseas. The automaker further amplifies its safety commitment through high-visibility displays at Dubai International Airport, the world's busiest international travel hub, proclaiming its core safety philosophy: "Safety, for Family." Leveraging its industry-leading battery safety technology, Chery is accelerating its global hybrid market expansion, turning its vision of "Let everyone enjoy five-star protection" into a tangible reality for customers worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
2 hours ago
- Korea Herald
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics
SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics, unveiled two new technologies at ADLM 2025 in Chicago (July 29–31) designed to advance laboratory automation and data-driven infectious disease monitoring. The company introduced CURECA™, world's first fully unattended PCR automation system, and STAgora™, a real-time data analytics platform intended to support earlier detection and precision care. Chairman Highlights Next Step in Molecular Diagnostics "With CURECA™ and STAgora™, we are taking an important step toward the future of diagnostics," said Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, during a press conference with U.S. and global media on July 30. "Our goal is to enable laboratories worldwide to automate complex testing workflows and use diagnostic data more effectively, ultimately helping advance global efforts toward a world free from diseases." Today, most molecular testing systems remain only partially automated, dependent on skilled personnel for repetitive manual steps and fixed workflows that limit efficiency and scalability. CURECA™ Breaks the Limits of Automation to Reshape Global Diagnostics CURECA™ is the first system in the diagnostics industry designed to fully automate every step of PCR testing, including the traditionally manual pre-treatment stage. Seegene notes that achieving true full automation in diagnostics requires three key conditions: operation without highly trained professionals, continuous 24-hour processing, and uninterrupted specimen input. CURECA™ is designed to meet all three. Its dedicated module, CURECA™ Prep, processes a wide range of specimen types such as urine, blood, sputum, and stool, addressing one of the most persistent barriers to automation. With the module handling diverse specimen pre-treatment, the full CURECA™ system completes the entire PCR workflow from sample loading through nucleic acid extraction, amplification, and result analysis without manual intervention. The system is engineered for continuous 24-hour operation, aiming to minimize human error, improve workflow efficiency, and allow laboratories to allocate skilled staff to higher-value activities. Full automation has long been a challenge in diagnostics due to specimen variability and the reliance on trained personnel for repetitive pre-processing tasks. CURECA™ is intended to help laboratories overcome these constraints by providing a scalable and adaptable system that can be configured to fit different lab sizes and workflows. CURECA™ Prep could also potentially extend to other testing fields, such as clinical chemistry and immunodiagnostics, as Seegene continues to explore broader automation solutions. STAgora™ Transforms Diagnostic Data into Real-Time Clinical Intelligence STAgora™ is Seegene's latest platform, designed to collect and analyze PCR testing data in real time, providing laboratories with broader context to inform diagnostic workflows. The platform includes more than 40 analytical tools, offering functions such as infection trend tracking, hospital-level positivity monitoring, and multi-pathogen co-infection pattern analysis. Rather than serving as a simple data repository, STAgora™ is built as an integrated platform intended to help laboratories derive meaningful, aggregated insights from testing data. Today, individual test results often provide limited information without broader reference points. STAgora™ is designed to address this by enabling hospitals to build their own statistical datasets and compare aggregated data across institutions, helping them detect infection patterns faster and support more informed decision-making. The data shared through the platform is de-identified and formatted according to each institution's requirements, supporting secure, real-time exchange at local, national, or global levels. Advancing Toward a World Free from All Diseases Dr. Chun reiterated Seegene's long-term vision of building "a world free from diseases" noting that the introduction of CURECA™ and STAgora™ completes the company's five core technology pillars. These include Seegene's proprietary PCR technology, the SGDDS (Seegene Digitalized Development System) for automated assay development, its global Technology-Sharing Initiative, and now the addition of fully automated PCR testing and real-time data analytics capabilities. Industry experts at ADLM 2025 expressed strong interest in Seegene's new technologies. Jamel Giuma, President and CEO of Miami based laboratory IT consulting firm JTG Consulting Group, said, "I've attended many ADLM conferences over the years, and CURECA™ is one of the most innovative solutions I have seen so far. I believe it has the potential to simplify laboratory workflows, reduce the burden on lab personnel, and greatly enhance overall operational efficiency." "With CURECA™ and STAgora™, we're addressing long-standing barriers in molecular diagnostics," Dr. Chun added. "Just as smartphones and electric vehicles transformed their industries, we believe these technologies will redefine what is possible in diagnostic testing, helping laboratories worldwide achieve true automation, unlock the value of diagnostic data, and ultimately contribute to building a world free from diseases." Disclaimer CURECA™ and STAgora™ demonstrated at ADLM 2025 are pre-commercial technologies under development, not commercially available, and are not currently cleared for clinical diagnostic use in any jurisdiction.
Korea Herald
5 hours ago
- Korea Herald
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application
• Successful validation of payloaded anti-colibactin toxin phage using IMPA ™ technology • Demonstrated ' Dual-target Therapeutic Strategy ' by bacterial eradication and toxin neutralization • Filed the US patent application for the candidate substance and preclinical studies including PoC underway BOSTON and SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Recently, a specific genotype of E. coli that may cause colorectal cancer has been detected in commonly eaten leafy vegetables such as lettuce, raising consumer concerns. Among these strains, pks+ E. coli is of particular concern. This bacterium produces a toxic substance in the intestine that causes DNA damage (ICLs, Interstrand Cross-Links), which leads to DSBs (Double Strand Breaks), and has been shown in numerous studies, including Nature (2023), to increase the risk of colorectal cancer over time. Amid this situation, as an innovative bacteriophage technology development company, iNtRON Bio proposes a new possibility for microbiome-based anticancer drugs in treating colorectal cancer—considered a hard-to-treat disease—by applying our phage engineering technology called IMPA™. iNtRON Bio has been developing PHAGERIA Ⓡ, an immunotherapeutic targeting gut bacteria, and through the IMPA™ phage engineering technology developed in-house, iNtRON Bio has secured a new drug candidate payloaded with a substance that effectively eliminates colibactin ,a major causative agent of colorectal cancer and have filed a related US patent application. The phage engineering technology IMPA™ (Intelligent Modular Phage Assembly) was formerly known as the "robot bacteriophage." With the recent US patent application, it was named to clearly reflect the function as a technology for engineering modular phages (mock-up phages) that can carry therapeutic payloads. This achievement is the result of combining transposon mutagenesis, CRISPR/Cas-based forward/reverse genetics, and AI-driven analysis capabilities to explore the possibility of delivering various functional payloads. In particular, it is highly significant that iNtRON Bio successfully loaded a payload targeting colibactin ,deeply involved in colorectal cancer, onto the surface of the phage and, for the first time globally, confirmed its effectiveness. In other words, iNtRON Bio has demonstrated a dual-targeting therapeutic approach that not only eliminates pks+ E. coli, which is a main cause of colorectal cancer, but also neutralizes the toxin secreted by this bacterium. This includes verifying colibactin's role in cancer development, confirming the suppressive effect of modular phage on colorectal cancer, and proving the phage's colibactin-degrading ability—resulting in successful proof-of-concept studies and related patent acquisition. Simply put, the core of this development is that a colibactin-degrading protein was applied as a payload on the phage's protein shell, known as the capsid. Like a precision-guided missile with a warhead, the engineered phage specifically infects pks+ E. coli, kills the bacteria, and at the same time removes the colibactin toxin already secreted by the bacterium using the enzyme carried in the capsid—offering a dual therapeutic effect. Recently, the field of bacteriophage engineering is gaining attention globally. IMPA™ technology is not only a unique platform technology differentiated from other companies, but also serves as strong evidence that it can function as an actual drug delivery platform beyond simple research use. It is encouraging that iNtRON Bio's research has overcome key limitations of conventional phage-based technologies, such as decreased payload activity and phage structural instability when therapeutic substances are loaded. By confirming that the payload retains its original function, iNtRON Bio has demonstrated that it has successfully overcome high technical hurdles. The engineered phages are not merely for research purposes but were selected and validated through multiple tests with real-world and human applications in mind. iNtRON Bio has applied an advanced AI-driven optimization platform technology, refined it with great care, and plan to extend its application to other development fields for ongoing innovation. This achievement is not only a remarkable advancement in phage engineering technology but will also become a driving force for discovering innovative microbiome drug candidates through integration with other phage-based platform technologies of iNtRON Bio. It will proceed smoothly with preclinical studies including proof-of-concept (PoC) testing for combination effects with existing colorectal cancer therapies. In addition, IMPA™ phage engineering technology will be applied more broadly to ADC drug development, anti-cancer agent, and vaccines, as iNtRON Bio continues to strengthen our global technological competitiveness in these fields.
Korea Herald
6 hours ago
- Korea Herald
DFI Teams Up with Technology Partners to Deliver ESG-Driven AI Solutions and Rugged Edge Systems for Mission-Critical Applications at Automation Expo 2025
TAIPEI, Aug. 5, 2025 /PRNewswire/ -- DFI, a global leader in embedded motherboards and industrial computers, will present its latest AI-powered and application-driven embedded platforms at Automation Expo 2025 from August 11–14 at Booth E16-E17, Hall 6, Bombay Exhibition Centre, Mumbai. Engineered for mission-critical tasks and extreme environments, these innovations are tailored to the evolving needs of automation, transportation, medical, and defense industries. According to a research report, India's industrial PC market is projected to grow at a 10.1% CAGR (2020–2026), driven by automation, robotics, medical, transportation, and other Industry 4.0 applications. Aligned with India's growing automation market, DFI offers Bureau of Indian Standards (BIS)-approved industrial systems built to meet strict requirements for quality, reliability, and safety. For harsh environments, the ECX700-ADP meets IP67/69K and MIL-STD-810G standards, offering advanced connectivity and low-latency 5G—ideal for AMR deployments in Industry 4.0 environments. DFI's collaboration with industrial AI partner LivNSense takes center stage with ESG-ready, AI-powered solutions. These solutions integrate DFI's EC600-series, EC700-ASL, in-vehicle systems, and the newly launched Edge AI server with LivNSense's VICAS AI engine for real-time safety detection at the edge. Coupled with the GreenOps platform, the solutions enable smarter, safer, more sustainable operations in mining, factory safety, and beyond. DFI will also deliver high-performance platforms for tightly regulated sectors such as transportation, defense and medical. For transportation, DFI will showcase the EN50155-compliant UPS-IP300 for efficient and reliable railway operations, alongside rugged in-vehicle systems like the VC700-ASL—built to meet E-mark and ITxPT standards, and tested to MIL-STD-810G for vibration and shock resilience. Within the defense sector, DFI highlights the ultra-compact QRB812 OSM with a live scouting drone demo for commercial UAVs applications, along with the COM-HPC RPS9HC, designed for extreme field use. Across medical applications, DFI introduces IEC 60601-compliant AI servers and medical-grade panel PCs for diagnostics, monitoring, and edge-based imaging. To support diverse AI workloads, DFI will also present the EC700-ADN with DEEPX NPU for low-latency inference and hybrid x86- and ARM-based platforms X6-MTH-ORN / X6-ORN—also featured at the Taiwan Excellence Pavilion (Hall 6, I2-J2). For press release materials, photos, and videos, please download them from the cloud: About DFI Founded in 1981, DFI is a global leading provider of high-performance computing technology across multiple embedded industries. With its innovative design and premium quality management system, DFI's industrial-grade solutions enable customers to optimize their equipment and ensure high reliability, long-term life cycle, and 24/7 durability in a breadth of markets including Industrial Automation, Medical, Gaming, Transportation, Energy, Mission-Critical, and Intelligent Retail.
